Roberto Contieri

Urologist @istitutotumori
via @HumanitasMilano @MDAndersonNews @NKI_nl
Member @EAU_YAUrotheli
Member @IBCG_BladderCA

[Roberto Contieri @RobertoContieri]

❓️Can we avoid ReTURBT in selected patients with T1 NMIBC? ✅️ According to our study YES!
👥️A response-based approach can spare up to 71% of ReTURBT reducing overtreatment

Full paper➡️https://t.co/dmugDLY4Wm

@EurUrolOncol @urotoday @Uroweb @oncodaily @IBCG_BladderCA

[Francesco Massari @fmassari79]

🚨 Just published in @CHematology

We confirms the benefit of perioperative strategies in #MIBC.

Huge thanks to all co-authors, especially @vmollica7 for the brilliant idea! 👏
@shilpaonc @drenriquegrande @giannatempopatr @OncoAlert @OncoDailyGU

[OncoDaily GU @OncoDailyGU]

IBCG2026 Celebrates 20 Years of Advancing Bladder Cancer Care - Roberto Contieri

@RobertoContieri

https://t.co/060VU6OSEC

[MolinetteUrology @UroMolinette]

🩺 UROTHELIAL CANCER UPDATE 2026 🔬 Meets the Guidelines, Challenges the Decisions. Join international experts for a turning point in urothelial cancer management!
🗓️ 18/09 @unito @cittasalute_to @UroMolinette
👨‍🏫 Chairs: Prof. @paolo_gontero & Prof F Soria
https://t.co/WMnVmJYwej

[OncoAlert @OncoAlert]

Three landmark studies. One network meta-analysis. Which perioperative strategy currently shows the strongest signal for improving survival in muscle-invasive bladder cancer? This analysis compares today's leading approaches and explores what the evidence can—and cannot—tell us.

Article👉 https://t.co/CJwzMnlu3C

Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials

This network meta-analysis evaluated perioperative treatment strategies for muscle-invasive #BladderCancer using data from three randomised trials. Compared with gemcitabine–cisplatin, both enfortumab vedotin–pembrolizumab and gemcitabine–cisplatin plus durvalumab📈 improved overall survival, event-free survival, and pathological complete response, with enfortumab vedotin–pembrolizumab ranking highest across outcomes.

Although based on indirect comparisons within a sparse network, these findings help contextualise emerging perioperative treatment options and inform clinical decision-making.

@albisinnidoc
@andreamari08
@FraClaps
@RobertoContieri
@agallioli
@DavDandrea
@E_Laukhtina
@wojciechpiotrk1
@elijeandin
@Luca_Afferi
@f_delgiudice
@UroMoschini
@LAUrology_NL
@Anto_cigliola
@CMercinelli
@MatteoSantoniMD
@BenjaminPradere
@AndreaNecchi

Pinging faculty
@DrChoueiri
@tompowles1
@apolo_andrea
@neerajaiims
@montypal
@Silke_Gillessen
@AOmlin
@brian_rini
@PGrivasMDPhD
@TiansterZhang
@AlbigesL
@cdanicas
@amerseburger
@sonpavde
@DrDanielHeng
@declangmurphy
@seanmmcbride
@HHammersMD
@shilpaonc
@DrRanaMcKay
@scserendipity1
@DrYukselUrun
@scocmem
@ravikanesvaran
@AmandaNizamMD
@drenriquegrande
@BraunMDPhD
@EfstathiouEleni
@nataliagandur
@crisbergerot

[Roger Li @UrogerliMD]

Results of #BOND3 @TheLancetOncol
👉112 pts c BCG UR CIS
👉75% CR
👉46% response at 12mo
👉Favorable AE profile
Compelling data to support use in #BCGURCIS
@MarkTysonMD #EdUchio @garysteinbergmd @tbivala1 #NealShore @JamesBurke34034 @cgoncology
https://t.co/2K2xpwWi4m

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Congratulations to @LauraBukavinaMD @jaymsiva @drjkaouk and @ClevelandClinic team on largest external validation of the IBCG IR NMIBC substratification model

📊 2822 patients | 20 years | 3-year recurrence by subgroup:
🟢 IR-low: 12%
🟡 IR-intermediate: 38%
🔴 IR-high: 77%

Progression followed the same stepwise pattern. Fine-Gray competing-risk models confirmed significance (p<0.001) - separation held on 12-month landmark analysis, ruling out early-event bias.

Yet more evidence that trials enrolling IR NMIBC should stratify by IBCG subgroup at enrollment to be clinically meaningful.
Conflating patients with 12% and 77% recurrence risk in the same trial arm is a fundamental problem.

Full text:
https://t.co/XsO8CUY3WS @IBCG_BladderCA

[UroToday.com @urotoday]

A multi-center study examines maintenance schedules for intermediate-risk #NMIBC. @RobertoContieri @IstTumori joins @UroDocAsh @UTMDAnderson to discuss the results which include two-year recurrence-free survival of 55% with no maintenance versus 78% with any maintenance. Classification and regression tree analysis identified optimal cutoff at more than six monthly instillations. #WatchNow on UroToday > https://t.co/G4Mw1OB0cA

[Max Kates @MaxKates]

1) Approval based on marginal improvements in efficacy (without improvement to CSS/OS)
2) Toxicity that isn't G5 (death) doesn't seem to impact approval. 10-15% serious autoimmune AEs in NMIBC is deemed ok
3) little weight given to efficacy vs toxicity balance of a drug

[Roberto Contieri @RobertoContieri]

Excellent lecture by @SScagliarini_ on the growing importance of patient-reported outcomes in oligometastatic RCC. A crucial reminder that beyond oncologic endpoints, understanding the patient perspective is essential to truly optimize treatment strategies.
@Synergy_Uro
@Uroweb

[Roberto Contieri @RobertoContieri]

Great pleasure having Prof. Axel Bex at @Synergy_Uro discussing the evolving landscape of locally advanced RCC. Excellent insights and stimulating discussion on current challenges and future directions in kidney cancer care. @eau_yuo
@EAUYAU_RenalCa
@UrowebESU
@EAU_Uroonco

[SYNERGY @Synergy_Uro]

The definitive #SYNERGY26 programme is out
📆 28–29 May | 📍 Naples

Locally-advanced &amp; Oigometastatic GU cancers Edition.

Program: https://t.co/Gx1pBWHGEk

[Roberto Contieri @RobertoContieri]

As every year, a packed room for the AUA-IBCG Forum, taking place right now in Salon H.

Great discussions and energy around the future of bladder cancer care and research.

#AUA2026 #BladderCancer @IBCG_BladderCA @UroDocAsh

[OncoDaily @oncodaily]

Synergy 2026: A Global Exchange on Prostate, Kidney, and Bladder Cancer - Roberto Contieri (@RobertoContieri)

https://t.co/A7ZOyVYLPL

#OncoDaily #Oncology #Cancer #Health #Medicine #MedX

[SYNERGY @Synergy_Uro]

SYNERGY 2026
🗓️ 28-29 May 2026
📍 Naples, Italy

Preliminary Program: https://t.co/Gx1pBWHGEk

✉️ Information &amp; participation: [email protected] - [email protected]

[Niyati Lobo @niyatilobo]

To escalate or de-escalate treatment in BCG-naive HR NMIBC?

Our thoughts on the recent JCOG1019 trial by Kitamura et al @EUplatinum

Free access to full text 👇🏽

https://t.co/xH5ios6rmT

@RobertoContieri @LAUrology_NL @UroDocAsh

[UroToday.com @urotoday]

A multi-center study examines maintenance schedules for intermediate-risk #NMIBC. @RobertoContieri @IstTumori joins @UroDocAsh @UTMDAnderson to discuss the results which include two-year recurrence-free survival of 55% with no maintenance versus 78% with any maintenance. Classification and regression tree analysis identified optimal cutoff at more than six monthly instillations. #WatchNow on UroToday > https://t.co/G4Mw1OB0cA

[European Urology Oncology @EurUrolOncol]

Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non–muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial by Roberto Contieri et al

Read the full article: https://t.co/6UJQAYDEE3

We thank the authors for trusting EUO to publish your work

@robertocontieri

@uroweb
@mroupret
@GPloussard
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@UroDocAsh
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect

[IBCG @IBCG_BladderCA]

The International Bladder Cancer Group Travel Award to support outstanding fellows and early-career academic faculty committed to advancing the field of bladder cancer is now offered annually to provide emerging leaders the opportunity to participate in the IBCG Annual Retreat.

Details at link: https://t.co/y8zbYkeLac
#BladderCancer #IBCG26

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Pleased to share that the 2026 @NCCN Bladder Cancer Guidelines now incorporate the @IBCG_BladderCa risk stratification framework for intermediate-risk NMIBC.

A milestone reflecting more than a decade of collaborative work by colleagues worldwide

https://t.co/VWFvAqRq4y

@UrogerliMD @drtanws @shilpaonc @pjhensley11 @mouwlab @AndreaNecchi @LAUrology_NL @AmirHorowitz @karima_oualla @PGrivasMDPhD @paolo_gontero @pcvblack @MaxKates @SpiessPhilippe @RobertoContieri @KKBree @LauraBukavinaMD @MRoupret @joanfundi @UroToday @BladderCancerUS @WorldBladderCan

[Aleksander Ślusarczyk @slusarczyk_alek]

We validated BCG failure classifications
~5-year progression ≈30% in both BCG-exposed and BCG-unresponsive groups—but salvage RC is used more often in BCG-unresponsive pts
https://t.co/ee1fJpr9Gq @Pietro9609 @UroMoschini @BenjaminPradere @RobertoContieri @SBoorjian @BJUIjournal